Description
DCZ0415 is a novel inhibitor of TRIP13, suppressing multiple myeloma progression.
Uses
DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients[1].
in vivo
DCZ0415 (ip; 50 mg/kg/day for 14 days) significantly reduces the growth of MM cells-induced tumors in immune-deficient mice[1].
| Animal Model: | Nude mice (6-weeks-old) with H929 775 cells[1] |
| Dosage: | 50 mg/kg |
| Administration: | Intraperitoneal injection; every day for 14 days |
| Result: | Significantly reduced the growth of MM cells-induced tumors.
|
target
DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity.
References
[1] Wang Y, et al. A Small Molecule Inhibitor Targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2019 Nov 15. pii: canres.3987.2018. DOI:
10.1158/0008-5472.CAN-18-3987
